Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit-positive, extensive-stage small-cell lung cancer

Clinical Lung Cancer

Volumn 11, Issue 4, 2010, Pages 223-227

  Schneider, Bryan ^a   Kalemkerian, Gregory ^b   Ramnath, Nithya ^b,c   Kraut, Michael ^d,e   Wozniak, Antoinette ^d   Worden, Francis ^b   Ruckdeschel, John ^d,f   Zhang, Xiaohui ^d   Chen, Wei ^d   Gadgeel, Shirish ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

^e PROVIDENCE HOSPITAL   (United States)

^f NEVADA CANCER INSTITUTE   (United States)

Author keywords

Autocrine growth pathway; c Kit inhibitor; Stem cell factor; Tyrosine kinase

Indexed keywords

CISPLATIN; IMATINIB; IRINOTECAN; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CAMPTOTHECIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT REFERRAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTO ONCOGENE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; DRUG RESISTANCE; ENZYME IMMUNOASSAY; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; PATHOLOGY; REMISSION; SALVAGE THERAPY; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CAMPTOTHECIN; CISPLATIN; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; REMISSION INDUCTION; SALVAGE THERAPY; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77957142100     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.028     Document Type: Article

References (28)

1. Navada S, Lai P, Schwartz AG, et al. Temporal trends in small cell lung cancer: analysis of the National Surveillance, Epidemiology, and End Results Database. J Clin Oncol 2006; 24(suppl 18):384s. (abstract 7082).
2. Hibi K, Takahashi T, Sekido Y, et al. Co-expression of the stem cell factor and the c-kit genes in small cell lung cancer. Oncogene 1991; 6:2291-2296
3. Plummer H, Catlett J, Leftwich J, et al. C-myc expression correlates with suppression of c-kit proto-oncogene expression in small cell lung cancer cell lines. Cancer Res 1993; 53:4337-4342
4. Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor in SCLC cell lines and xenografts. Br J Cancer 1993; 67:37-42.
5. Krystal GW, Carlson P, Litz J. Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins. Cancer Res 1997; 57:2203-2208
6. Krystal GW, Honsawek S, Litz J, et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000; 6:3319-3326
7. Krystal GW, Honsawek S, Kiewlich D, et al. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res 2001; 61:3660-3668
8. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-480
9. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-1037
10. van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38:S83-7.
11. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive stage small-cell lung cancer. N Engl J Med 2002; 346:85-91.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216 (Pubitemid 30099779)
13. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10.
14. Lee E. Statistical Methods for Survival Data Analysis, 3rd ed. Hoboken, NJ: Wiley & Sons, Inc.; 2003:76-91.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
16. Krystal GW, DeBerry CS, Linnekin D, et al. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1. Cancer Res 1998; 58:4660-4666
17. Johnson BE, Fischer T, Fisher B, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003; 9:5880-5887
18. Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trial of imatinib (STI571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005; 16:1811-1816.
19. Krug LM, Crapanzano JP, Azzoli CG, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein. Cancer 2005; 103:2128-2131
20. Spigel DR, Hainsworth JD, Simons L, et al. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol 2007; 2:854-861
21. Wolff NC, Randle DE, Egorin MJ, et al. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clin Cancer Res 2004; 10:3528-3534
22. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-4349
23. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003; 63:6272-6281
24. Burger H, den Bakker MA, Stoter G, et al. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 2003; 39:793-799
25. Tamborini E, Bonadiman L, Negri T, et al. Detection of overexpressed and phosphorylated wild-type receptor in surgical specimens of small cell lung cancer. Clin Cancer Res 2004; 10:8214-8219
26. Sihto H, Sarlomo-Rikala M, Tynninen O, et al. KIT and platelet derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 2005; 23:49-57.
27. Boldrini L, Ursino S, Gisfredi S, et al. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res 2004; 10:4101-4108
28. Batus M, Myint R, Coon J, et al. N-cadherin, E-cadherin, ERCC1, and c-kit expression in small cell lung cancer (SCLC) and potential for new therapeutic targets. J Clin Oncol 2009; 27(suppl): (abstract e22157).